Cargando…
Tocilizumab in the treatment of twelve cases with aa amyloidosis secondary to familial mediterranean fever
BACKGROUND: There is no established treatment of AA amyloidosis, a long-term complication of various chronic inflammatory diseases associated with increased mortality, such as familial Mediterranian fever (FMF). Recently there are few reports pointing out that tocilizumab(TCZ), an anti IL-6 agent ma...
Autores principales: | Ugurlu, Serdal, Hacioglu, Aysa, Adibnia, Yasaman, Hamuryudan, Vedat, Ozdogan, Huri |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5450086/ https://www.ncbi.nlm.nih.gov/pubmed/28558744 http://dx.doi.org/10.1186/s13023-017-0642-0 |
Ejemplares similares
-
Efficacy and safety of canakinumab in adolescents and adults with colchicine-resistant familial Mediterranean fever
por: Gül, Ahmet, et al.
Publicado: (2015) -
Canakinumab therapy in patients with Familial Mediterranean Fever
por: Ugurlu, S, et al.
Publicado: (2015) -
In Familial Mediterranean Fever, soluble TREM-1 plasma level
is higher in case of amyloidosis
por: Ugurlu, Serdal, et al.
Publicado: (2020) -
Assessment of Mean Platelet Volume in Patients with AA Amyloidosis and AA Amyloidosis Secondary to Familial Mediterranean Fever: A Retrospective Chart – Review Study
por: Bakan, Ali, et al.
Publicado: (2019) -
Long-term follow-up of secondary amyloidosis patients treated with tumor necrosis factor inhibitor therapy: A STROBE-compliant observational study
por: Esatoglu, Sinem Nihal, et al.
Publicado: (2017)